Skip to main content
Terug
Watch Compare

SeaStar Medical Holding Corp

Datakwaliteit: 100%
Ook genoteerd als ICUCW NASDAQ
ICU
NASDAQ Manufacturing Measuring & Analyzing Instruments
€ 3,86
▲ € 0,11 (2,93%)
6 months return
—
Momentum
Neutral
ROE
-164,13%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)814,07%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-164,13%
Onder sectorgemiddelde (-54,68%)
ROIC-129,93%
Net Margin-984,60%
Op. Margin-986,63%

Veiligheid

Debt / Equity
N/A
Current Ratio3,66
Interest Coverage-392,74

Waardering

PE (TTM)
-1,35
Boven sectorgemiddelde (-1,49)
P/B Ratio1,43
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -13,60 M

Price History

Financiële Trends

Koersdoel Analisten

2 analisten
Strong Buy
+133.2%
upside to target
Huidig
€ 3,86
Consensus Target
€ 9,00
€ 6,00
Laag
€ 12,00
Hoog
Vooruitzicht
Forward WPA
-€ 2,07
Omzet Sch.
2,80 M

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,83 · Rev Est: 437.500,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 4,40 -€ 1,80 -€ 1,30 -€ 0,80 — —
Estimate -€ 5,20 -€ 4,30 -€ 1,50 -€ 1,02 -€ 0,83 -€ 0,83
Verrassing +15,38% +58,14% +13,33% +21,18% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) 814,07% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -164,13% · Net Margin: -984,60%
Revenue (TTM) 1,23 M Net Income (TTM) -12,15 M
ROE -164,13% ROA -101,62%
Gross Margin 95,71% Operating Margin -986,63%
Net Margin -984,60% Free Cash Flow (TTM) -13,60 M
ROIC -129,93% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 3,66
Debt / Equity N/A Current Ratio 3,66
Interest Coverage -392,74 Asset Turnover 0,10
Working Capital 10,81 M Tangible Book Value 11,46 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -1,35 · EV/EBITDA: N/A
P/E Ratio -1,35 Forward P/E N/A
P/B Ratio 1,43 P/S Ratio 13,30
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 5,85 Fwd Earnings Yield N/A
FCF Yield -82,85%
Market Cap 16,41 M Enterprise Value 16,41 M

Per Share

EPS: N/A · FCF/Share: -3,41
EPS (Diluted TTM) N/A Revenue / Share 0,31
FCF / Share -3,41 OCF / Share -3,41
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 111,93% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 111,93%
SBC-Adj. FCF -14,35 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,23 M 135.000,0 — — —
Net Income -12,15 M -24,83 M -26,23 M -23,01 M 75.317,0
EPS (Diluted) — -6,63 -1,21 -2,80 —
Gross Profit 1,18 M 135.000,0 — — —
Operating Income -12,18 M -17,84 M -14,21 M -11,61 M -1,12 M
EBITDA — — — — —
R&D Expenses 7,52 M 9,11 M 5,97 M 2,82 M —
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 31.000,0 244.000,0 1,08 M 630.000,0 —
Income Tax 3.000,0 3.000,0 0,0 1.000,0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 14,16 M 4,66 M 3,51 M 4,77 M 105,93 M
Total Liabilities 3,74 M 6,84 M 17,38 M 13,00 M 10,93 M
Shareholders' Equity 10,42 M -2,18 M -13,87 M -8,24 M -10,57 M
Total Debt — 4,14 M 4,14 M — —
Cash & Equivalents — — — — 51.567,0
Current Assets 13,58 M 3,77 M 2,31 M 3,04 M —
Current Liabilities 3,74 M 6,84 M 13,05 M 5,35 M 376.702,0

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -1,4 -1,5
P/B 1,4 1,6
ROE % -164,1 -54,7
Net Margin % -984,6 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3